CliniCally relevant d rug transporters - brainGuide Improve your drug development programmes by applying effective testing and modelling ... Capsugel, Division of ... Quantitative

12th – 14th April 2011 | Maritim pro Arte Berlin

To Register | T +49 (0)30 20 91 33 30 | F +49 (0)30 20 91 33 12 | E [email protected] | www.drug-transporters.com/MM

• Improve your drug development programmes by applying effective testing and modelling methodology for drug transporter activity

• Learn how to conduct in vitro-to-in vivo and preclinical-to-clinical translation of transport data

• Discuss the impact of regulatory authorities and the ITC whitepaper on drug transporter strategies

• Benefit from recent studies from leading pharmaceutical and academic scientists

• Gain full understanding of the role of drug transporters in toxicity

Hear international case studies from

leading companies and institutes:

• Sanofi-Aventis Deutschland GmbH, Germany

• Capsugel, Division of Pfizer, Belgium

• University of Tokyo, Japan

• Genentech Inc., Member of the Roche Group, USA

• Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Germany

• Friedrich-Alexander-University Erlangen-Nürnberg, Germany

• University of Manchester, UK

• Newcastle University, UK

• University of Heidelberg, Germany

• University Halle-Wittenberg, Germany

• University of Toronto, Canada

• Tohoku University, Japan

• GlaxoSmithKline, UK

• Johnson & Johnson, Belgium

Researched and developed by

Visit our download center for free white papers, articles and much more! www.drug-transporters.com/MM

A Neurovascular Unit and Biochemical Barrier Function

B ABC of Modelling Transporter Data (I) - Principles and Practical Know How

C ABC of Modelling Transporter Data (II) - Applications and Combining In Vitro Knowledge with Clinical Observations

D Species differences in drug transport and drug metabolism - do we have good enough experimental models to work with?

INTERACTIvE WoRKSHoP DAy | Thursday, 14th April 2011

HIGHlIGHTS

CliniCally relevant drugtransporters

© M

ike

Kie

v -

Foto

lia.c

om

SAVe

up to €

290,-

with

our

Early

Birds i

f you b

ook by

the 1

8th Fe

bruar

y 201

1!

Mechanistic modelling of transporter driven PK – Drug-drug interaction – Translation of transport data

Ph.D. Tetsuya Terasaki, Distinguished Professor Division of Membrane Transport and Drug Targeting Department of Biochemical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku University, Japan

Dr. Hiroyuki Kusuhara, Associate Professor Department of Molecular PK, University of Tokyo, Japan

Ph.D. Reina Bendayan, Professor and Associate Dean, Graduate Education, Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada

Ph.D. Maarten T. Huisman, DMPK Belgium, Teamleader PK-lab Belgium & Leader J&J Center of Expertise Transporters, Johnson & Johnson, Belgium

Media Partners

2nd annual

Team Discounts

We are offering attractive TeamDiscounts, please contact us!

Dear colleague,

Since IQPC's first meeting on clinically relevant drug transporters in 2009 considerable progress has been made in understanding the influence of membrane transporters on drug absorption, disposition, metabo-lism and elimination. Although the knowledge regarding the conduct of transporters assays and data inter-pretation has expanded dramatically over the past years, in vitro-to-in vivo and preclinical-to- clinical translation of transport data is still a very challenging field.

With the draft EMEA guidance, the ITC whitepaper and FDA regulation under way, performing well-designed transporter experiments has become crucial for pharmaceutical companies.

So don´t miss IQPC's second conference

CliniCally relevant drug transportersMechanistic modelling of transporter driven PK – Drug-drug interaction –

Translation of transport data


which will bring together pharmaceutical and academic scientists. Areas of discussion will include:

• Effective testing and modelling methodology• In vitro-to-in vivo and preclinical-to-clinical translation of transport data• Impact of regulatory authorities and the ITC whitepaper

We are looking forward to meeting you in Berlin.

Kind regards

Sebastian KrzonkallaProduct Manager

Sponsorship

We have a variety of packagesavailable to suit your requirements. For all Sponsorship and Exhibitionopportunities call Neil Corteen: +49 (0)30 20 91 32 75 or email [email protected].

Register for our email updates!

Get the latest news on our events, additional download possibilities, early bird deadlines and much more! Register now atwww.drug-transporters.com/MM.

For further information

please visit our websitewww.drug-transporters.com/MM or contact Doreen, Hannah or Mark on +49 (0)30 20 91 32 74 or email [email protected].

Media Partners

PharmaVOICE magazine addresses the challenges and trends impacting the life-sciences industry. PharmaVOICE's subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers. www.pharmavoice.com

www.PharmCast.com is the world leading website designed specifically for pharmaceutical, clinical and biotechnology professionals. www.Pharm Cast.com brings up-to-date information on pharmaceutical patents, FDA, news, jobs and Buyer's Guide to our visitors. It was created and is maintained by pharmaceutical and biotechnology professionals. Visit www.PharmCast.com and discover for yourself why it is so popular among professionals. www.pharmcast.com

G.I.T. Laboratory Journal Europe reports on all important topics relevant for the European laboratory market. Latest developments in analytics, technology, lab equipment, furniture and lab automation are displayed either in application notes from the chemical, food and pharmaceutical industry or in scientific articles. Bimonthly, G.I.T. Laboratory Journal Europe reaches 27,000 personalised addresses in industrial R&D and scientific institutions throughout Europe. www.laboratory-journal.com

CHEManager Europe supplies managers and executives with essential market news, interviews to assist with decision-making, product applications and more. Leading personalities from the areas of scientific research, business and politics express their positions on current topics. All of this enables CHEManager Europe to establish itself as an image vehicle for the Chemical and Life Science industries. With a circulation of 15,000, CHEManager Europe is the most effective medium for this target group. Please note, the German market can be accessed through the German sister publication CHEManager, which is the leading publication (circulation: 43,000) in Germany for this market! www.chemanager-online/en




Highlight

Highlight

09:00 Registration & coffee

09:30 Chairman´s welcome and opening address Ph.D. Maarten T. Huisman, DMPK Belgium, Teamleader PK-lab Belgium & Leader J&J Center of Expertise Transporters, Johnson & Johnson, Belgium

Absorption

09:45 The influence of drug transporters on drug absorption • Relevant transporters in the gut • uptake transporters • Efflux Transporters Ph.D. Sven Stegemann, Director Global Pharmaceutical Business Development Capsugel, Division of Pfizer, Belgium

Distribution / Metabolism / Elimination

10:30 Human uptake and efflux transporters and their role in hepatic drug absorption, metabolism, and elimination – Focus on lIvER • Relevance of transport proteins for drug half-life, uptake, and action • Drug uptake into human hepatocytes by OCT and OATP proteins • Drug efflux into bile / into the circulation by efflux transporters (e.g. MRP2, MRP4, MDR1 P-glycoprotein) • In vitro systems to measure uptake and efflux transporters • Pharmacogenetics of drug transporters PD Dr. Anne Nies, Head Membrane Transport Proteins, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart University of Tübingen, Germany

11:15 Refreshment break & networking

11:45 Focus on KIDNEy Role of organic ion transporters in the renal elimination of drugs: clinical investigation using in vivo inhibitors • In vivo inhibitors for OAT1, OAT3, MATE1 and MATE2-K • In vitro evaluation of transporter function using human kidney slices and brush border membrane vesicles • Drug-drug interaction studies using probe substrates and inhibitors in healthy subjects • Endogenous substrates of renal organic ion transporters Dr. Hiroyuki Kusuhara, Associate Professor Department of Molecular PK, University of Tokyo, Japan

12:30 Drug Transport across the Blood-Brain Barrier (BBB) • Structure and function of the BBB • Regulation and Modulation of transporters • Models of the BBB • Drug Delivery Systems for CNS-delivery Prof. Dr. Gert Fricker, Director at the Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Germany

13:15 Networking luncheon

14:15 Glial Cells: Secondary Barriers to Drug Permeability• Contribution of glial cells to the neurovascular unit barrier function• Localization and functional expression of ATP-Binding Cassette (ABC) membrane transporters in glial cells (astrocytes and microglia)• Regulation of ABC transporters by HIV viral coat protein, gp-120, in glial cells, a cellular target of HIV infection• Complexity of drug-transporter interactions in the context of HIV-associated inflammation and oxidative stressPh.D. Reina Bendayan, Professor and Associate Dean, Graduate Education, Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada

15:00 Impact of regulatory authorities and the ITC Whitepaper • Impact of FDA regulation • Impact of ITC Whitepaper • Interpretation and application of the draft EMEA guidance • Japan Dr. Dietmar Weitz, Laboratory Head, MPK Metabolism & In vitro Systems, Sanofi-Aventis Deutschland GmbH, Germany


Transporters & Toxicity

16:15 Renal organic anion transporters: Is regulation of expression involved in renal damage after ischemia? • OAT1 (Slc22a6) • OAT3 (Slc22a8) • Regulation of expression • Renal ischemia and reperfusion • Renal outcome PD Dr. Christoph Sauvant, Laboratory Head, University Halle-Wittenberg, Germany

17:00 Closing remarks of the chairman and end of conference day one

CoNFERENCE DAy oNE | Tuesday, 12th April 2011

What’s in your download center?

The purpose of the download center is to provide you with relevant content to enhance your knowledge of current trends and industry news. All content is 100% complimentary, easy to download, and current.Featuring live podcast interviews which you can stream on your computer or portable device, up-to-date news from local and international sources, industry whitepapers, and other relevant content – the download center is your online portal to expand your knowledge and add value to your business.We encourage your feedback and participation, for all comments or enquiries please contact Doreen, Hannah or Mark on +49 (0)30 20 91 32 74 or [email protected] free white papers, articles and much more! www.drug-transporters.com/MM


Highlight

Highlight

08:30 Registration & coffee

09:00 Chairman´s welcome and opening address Ph.D. Sven Stegemann, Director Global Pharmaceutical Business Development Capsugel, Division of Pfizer, Belgium

Mechanistic Modelling of Transporter Driven PK & DDI

09:15 Introduction into in vitro / in vivo models • Overview of key in vitro / in vivo tools • Advantages/Disadvantages • IVIVC Ph.D. Maarten T. Huisman, DMPK Belgium, Teamleader PK-lab Belgium & Leader J&J Center of Expertise Transporters, Johnson & Johnson, Belgium

Laurent Salphati, Scientist, Genentech Inc., Member of the Roche Group, USA


11:15 Transporter Pharmacoproteomics: Protein quantification for nonclinical and clinical research in the industry and the hospital • Introduction: Why transporter protein quantification is important ? • Methodology: How to quantify transporter protein by LC- MS/MS ? (Detection limit, dynamic range, reproducibility) • Application Quantitative evaluation of in vitro culture system based on the transporter protein quantification Quantitative evaluation of in vivo animal model based on the transporter protein quantification in mouse, monkey and human Reconstruction of in vivo brain distribution for several drugs based on the mdr1a/MDR1 protein quantification at the BBB Reconstruction of in vivo brain drug distribution in the diseased animal model based on the mdr1a/MDR1 protein quantification at the BBB Quantitative evaluation of drug efflux transporters in the malignant glioblastoma and metastatic brain tumor patients based on the transporter protein quantification • Perspective Ph.D. Tetsuya Terasaki, Distinguished Professor, Division of Membrane Transport and Drug Targeting Department of Biochemical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tohoku University

12:15 The mechanistic understanding and prediction of renal drug-drug interactions with methotrexate: An industry perspective • An introduction to the PK and ADME of methotrexate (with a focus on transporter mediated disposition) • Methotrexate drug-drug interactions, a mechanistic understanding • Prediction of methotrexate drug-drug interactions using in-vitro data from organic anion transporter assays • Gaps in our knowledge around methotrexate drug-drug interaction and how this is being addressed (includes PBPK modelling efforts)

James Clarke, Scientist, DMPK, GlaxoSmithKline R&D, UK

13:00 Networking luncheon

14:00 Interplay of Metabolism and Transport in Determining oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model Amin Rostami-Hodjegan, Professor of Systems Pharmacology, School of Pharmacy and Pharmaceutical Sciences University of Manchester Director of Scientific Development, Simcyp limited Blades Enterprise Centre

14:45 Development of a novel human proximal tubule cell model to understand the renal handling of drug molecules • We have developed a fully differentiated Human primary proximal tubule cell model • Cell monolayers exhibit vectorial transport of key prototypic substrates • We can quantify the contribution of individual transporters to the handling of drug molecules • We can identify key sites of drug-drug interactions • We can study transporter expression and function in response to substrate exposure Dr Colin D A Brown Ph.D, Epithelial Research Group Institute for Cell & Molecular Bioscience, Medical School, Newcastle University


16:00 Modelling of Transporter Driven DDI • uptaketransporter and exportpumps relevant for DDI • hepatic and renal Transporters • In vitro analysis of DDIs • In vivo relevance of DDIs PD Dr. Jörg König, Institute of Experimental and Clinical Pharmacology and Clinical Toxicology, Friedrich-Alexander-University Erlangen-Nürnberg, Germany

16:45 Transporter investigations to explain mechanisms of clinical DDIs • Astrazeneca drug development cases • Application of assays for uptake and efflux transporters • Preclinical-to-clinical translation of transporter data Johan Palm, PhD, Clinical Pharmacology & DMPK, Mölndal, AstraZeneca R&D Mölndal, Sweden

17:30 outlook Transporters Ph.D. Maarten T. Huisman, DMPK Belgium, Teamleader In Vitro Lab DMPK Belgium and Leader J&J´s Center of Expertise Transporters, Johnson & Johnson, Belgium

17:45 Closing remarks of the chairman and end of conference day two

CoNFERENCE DAy TWo | Wednesday, 13th April 2011


INTERACTIvE WoRKSHoP DAy | Thursday, 14th April 2011

Workshop A09:00 – 12:00 Neurovascular Unit and Biochemical Barrier Function

Limited drug penetration is an obstacle that is often encountered in the treatment of CNS diseases including human immuno-deficiency virus type-1 (HIV-1) encephalitis (HIVE) and brain tumors. One mechanism that may contribute to this phenomenon is the expression of ATP-binding cassette (ABC) drug efflux transporters [i.e., P-glycoprotein (P-gp), Multidrug Resistance-Associated Proteins (MRPs/Mrps), Breast Cancer Resistance Protein (BCRP; also known as ABCG2)] at the blood-brain barrier (BBB). We have demonstrated that ABC transporters are not only expressed in brain microvessel endothelial cells which form the BBB but also in glial cells, the primary target of HIV infection in the brain. We propose that the localisation of these transporters in brain parenchyma may also contribute to the low accumulation and altered distribution of several therapeutic compounds including antiretroviral drugs and chemotherapeutic agents in the brain by creating a “secondary barrier”. This workshop will discuss the potential contribution of glial cells to the neurovascular unit barrier function and drug resistance in the context of HIV infection and cancer.

Ph.D. Reina Bendayan, Professor and Associate Dean, Graduate Education Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada

Workshop B09:00 – 12:00 ABC of Modelling Transporter Data (I) - Principles and Practical Know How

The session will give a step-by-step guide to enable participants in understanding the terms applied within modelling are-ana as applied to transporters. Transporter related experiments will be revisited and pitfalls will be highlighted to assist the researchers in finding their way through the complex datasets obtained via various in vitro techniques. All participants will have the opportunity of experiencing interactive problem solving sessions facilitated by experienced tutors.

Workshop Lead: Amin Rostami-Hodjegan, Professor of Systems Pharmacology, School of Pharmacy and Pharmaceutical Sciences University of Manchester, UKDirector of Scientific Development, Simcyp limited Blades Enterprise Centre, UK

Worksop Tutors:Mr Matthew Harwood and Dr Fania Bajot, Research Scientists, Simcyp limited, Sheffield, UK

Workshop C13:00 – 16:00

ABC of Modelling Transporter Data (II) - Applications and Combining In vitro Knowledge with Clinical observations

The session deals in details with complexity of the models related to transporters in gut and liver. The session touches upon transporter modelling in brain and kidneyi before desending to practical examples involving the applications of the modelling approach to answer observations related to oral bioavailability, hepatic clearance, drug-drug interactions (DDIs), and drug distribution to different organs. Impact of population variability and approaches to handling genetic variations are also discussed.

Workshop Lead: Amin Rostami-Hodjegan, Professor of Systems Pharmacology, School of Pharmacy and Pharmaceutical Sciences University of Manchester, UKDirector of Scientific Development, Simcyp limited Blades Enterprise Centre, UK

Worksop Tutors:Mr Matthew Harwood and Dr Fania Bajot, Research Scientists, Simcyp limited, Sheffield, UK

Workshop D13:00 – 16:00

Species differences in drug transport and drug metabolism - do we have good enough experimental models to work with?

What technologies should we be thinking of developing?

• Humanised animal models • Computer PK-PD models • Primary in-vitro human cell models ( hepatocyte sandwich, proximal tubule monolayers) • Stem cell derived models?

Dr Colin D A Brown Ph.D, Epithelial Research Group, Institute for Cell & Molecular Bioscience, Medical School, Newcastle University

Team DiscountsWe are offering attractive Team Discounts, please contact us!

For further information pleasevisit our website www.drug-transporters.com/MMor contact Doreen, Hannah or Mark on +49 (0)30 20 91 32 74 or email [email protected].


PDFW

If undeliverable, please return to: IQPC GmbH | Friedrichstraße 94 | D-10117 Berlin, Germany

Cancellations and Substitutions

CANCELLATIONS AND SUBSTITUTIONS DELEGATES MAy BE SuBSTITuTED AT ANy TIME. IQPC GESELLSCHAFT FüR MANAGEMENT KONFERENzEN MBH DOES NOT PROVIDE REFuNDS FORCANCELLATIONS. HOWEVER, SAVE WHERE WRITTEN NOTICE OF CANCELLATION IS RECEIVED MORE THAN SEVEN (7) DAyS PRIOR TO THE CONGRESS, A CREDIT TO THE VALuE PAID AT THAT DATE WILL BE ISSuED, WHICH MAy BE uSED AGAINST ANOTHER IQPC GMBH CONGRESS FOR uP TO ONE yEAR FROM ITS DATE OF ISSuE. FOR CANCELLATIONS RECEIVED SEVEN (7) DAyS OR LESS PRIOR TO AN EVENT (INCLuDING DAy SEVEN), NO CREDIT WILL BE ISSuED. IN THE EVENT THAT IQPC GMBH CANCELS AN EVENT, PAyMENTS RECEIVED AT THE CANCELLATION DATE WILL BE CREDITED TOWARDS ATTENDANCE AT A FuTuRE IQPC GMBH CONGRESS OR, IN THE EVENT OF A POSTPONEMENT By IQPC GMBH, A RESCHEDuLED DATE. IF THE DELEGATE IS uNABLE TO ATTEND THE RESCHEDuLED EVENT, THE DELEGATE WILL RECEIVE A CREDIT IN LIEu OF PAyMENTS MADE TOWARDS A FuTuRE IQPC GMBH EVENT, VALID FOR ONE yEAR FROM THE DATE OF ISSuE. IQPC GMBH IS NOT RESPONSIBLE FOR ANy LOSS OR DAMAGE AS A RESuLT OF A SuBSTITuTION, ALTERA-TION, POSTPONEMENT OR CANCELLATION OF AN EVENT DuE TO CAuSES BEyOND ITS CONTROL INCLuDING, WITHOuT LIMITATION, NATuRAL DISAS-TERS, SABOTAGE, ACCIDENT, TRADE OR INDuSTRIAL DISPuTES OR HOSTILITIES.yOUR DETAILS PLEASE CONTACT OuR CuSTOMER SERVICE MANAGER (TEL: +49 (0)30 20913330 OR [email protected]) AND INFORM THEM OF ANy INCORRECT DETAILS WHICH WILL BE AMENDED ACCORDINGLy OR IF yOu PREFER NOT TO GET INFORMATION PER FAx EMAIL OR PHONE ANyMORE.SPEAKER CHANGES OCCASIONALLy IT IS NECESSARy FOR REASONS BEyOND OuR CONTROL TO ALTER THE CONTENTS AND TIMING OF THE PROGRAMME OR THE IDENTITy OF THE SPEAKERS.DATA PROTECTION PERSONAL DATA IS GATHERED IN ACCORDANCE WITH THE DATA PROTECTION ACT 1998. yOuR DETAILS MAy BE PASSED TO OTHER COMPANIES WHO WISH TO COMMuNICATE WITH yOu OFFERS RELATED TO yOuR BuSINESS ACTIVITIES. IF yOu DO NOT WISH TO RECEIVE THESE OFFERS, PLEASE TICK THE BOx BELOW.

PLEASE DO NOT PASS My INFORMATION TO ANy THIRD PARTy.

Payment Terms

Payment is due within 2 weeks after receipt of the invoice.

Venue and Accommodation

Maritim pro Arte BerlinFriedrichstraße 15110117 Berlin, GermanyTel.: +49 (0)30 2033 4414Fax: +49 (0)30 2033 4090Email: [email protected]

Accommodation: A limited number of reduced rate rooms are available at the conference hotel. Accommodation canbe booked by calling the central reservation number.Please always quote the booking reference IQPC-Berlin. Hotel accommodation and travel costs are not includedin the registration fee.

BOOKINGCODE

Fax: +49 (0)30 20 91 33 12

Post: IQPC Gesellschaft für

Management Konferenzen mbH

Friedrichstraße 94

10117 Berlin, Germany

Online: www.drug-transporters.com/MM

Email: [email protected]

For further information

Phone: +49 (0)30 20 91 33 30

4 Ways to Register

© IQPC GESELLSCHAFT FüR MANAGEMENT KONFERENzEN MBH

Con

fere

nce

code

DE

1821

4.00

2

Delegate Details

PAy By BANK TRANSFER qUOTING REFERENCE DE18214.002:IQPC Gesellschaft für Management Konferenzen mbH,HSBC Trinkaus & Burkhardt AG, BLz 300 308 80, Konto-Nr. 430076019 IBAN: DE32 30030880 0430076019, SWIFT-BIC: TuBDDEDD

By CREDIT CARD: Please debit my credit card

Card No

Expiry date Security code

Cardholder’s name

Signature

Card billing address (if different from Company address)

By CHEqUE: Made payable to IQPC Gesellschaft für Management Konferenzen mbH

Please fill out in Capitals!DELEGATE Mr Mrs Ms Dr

Family Name First Name

Position Email

Telephone Fax

Organisation

Address

Postcode/Town

Approving Manager:

Signature

I agree to IQPC Gesellschaft für Management Konferenzen mbH payment terms.

yes, I would like to receive information about products and services via email.

Only one discount applicable per person.

CAN'T MAKE IT TO THE CONFERENCE? PURCHASE THE 2-DAy CONFERENCE DOCUMENTATION FOR € 595,- +VAT.

Payment Methods

Please indicate choice of workshop on Thursday, 14th April 2011Workshop A I Workshop B I Workshop C I Workshop D

/

yOUR DETAILS: PLEASE CONTACT OuR DATABASE MANAGER ([email protected]) AND INFORM THEM OF ANy INCORRECT DETAILS WHICH WILL BE AMENDED ACCORDINGLy

Early Bird(Book and pay by the 18th February 2011)

Standard Price

Platinum Package 2 day conference plus 2 workshops Save € 290,- € 2.609,- +VAT € 2.899,- + VAT

Gold Package 2 day conference plus 1 workshop Save € 260,- € 2.339,- +VAT € 2.599,- + VAT

Bronze Package 2 day conference € 2.199,- + VAT

Workshop Day € 1.399,- + VAT

Conference Packages

A: Neurovascular Unit and Biochemical Barrier FunctionB: ABC of Modelling Transporter Data (I) - Principles and Practical Know HowC: ABC of Modelling Transporter Data (II) - Applications and Combining In Vitro Knowledge with Clinical Observations D: Species differences in drug transport and drug metabolism - do we have good enough experimental models to work with?

CliniCally relevant drugtransporters

© M

ike

Kie

v -

Foto

lia.c

om


Documents

CliniCally relevant d rug transporters - brainGuide Improve your drug development programmes by applying effective testing and modelling ... Capsugel, Division of ... Quantitative